Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Epigenetics/epigenomics in human health or disease

Université de Montréal

$100,000.00

Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies

EF 2021-22

Résumé
Breast cancer is the most common and second deadliest cancer affecting women in North America. One of the subtypes of breast cancers is called the triple-negative breast cancer subtype and comprises highly aggressive tumors. Triple-negative breast cancer patients exhibit poor outcomes due to absence of long-term response to chemotherapy, leading to tumor relapse and metastatic progression. Identification of additional therapies to target this subtype of breast cancer is therefore a priority. One of the main issues with aggressive tumors like triple-negative breast cancer, is that the cancer cells can change their identity to better survive in hostile growth conditions and in treatment. The goal of this project is to identify the mechanisms that control how triple negative breast cancer cells change their identify in hostile environment and how these changes in identify contribute to modify their usage of nutrients and resources to generate energy and proliferate. We will also investigate how to target these adaptations in triple-negative breast cancer to prevent tumor growth and progression. The results generated from this project could allow the identification of new biological mechanisms that contribute to the progression of tumors. Investigating whether and how these new mechanisms can be targeted to develop improved pharmacological approaches for the treatment of poor prognosis triple-negative breast cancers.
Programme
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
448075
Name
Deblois Genevieve
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Keyworddelim
Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Cancer Therapy; Chromatin Accessibility; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification; Triple-Negative Breast Cancer
Abstract
Breast cancer is the most common and second deadliest cancer affecting women in North America. One of the subtypes of breast cancers is called the triple-negative breast cancer subtype and comprises highly aggressive tumors. Triple-negative breast cancer patients exhibit poor outcomes due to absence of long-term response to chemotherapy, leading to tumor relapse and metastatic progression. Identification of additional therapies to target this subtype of breast cancer is therefore a priority. One of the main issues with aggressive tumors like triple-negative breast cancer, is that the cancer cells can change their identity to better survive in hostile growth conditions and in treatment. The goal of this project is to identify the mechanisms that control how triple negative breast cancer cells change their identify in hostile environment and how these changes in identify contribute to modify their usage of nutrients and resources to generate energy and proliferate. We will also investigate how to target these adaptations in triple-negative breast cancer to prevent tumor growth and progression. The results generated from this project could allow the identification of new biological mechanisms that contribute to the progression of tumors. Investigating whether and how these new mechanisms can be targeted to develop improved pharmacological approaches for the treatment of poor prognosis triple-negative breast cancers.
Competitiondate
202104
Approvedterm2
1 yr 0 mth
Pinamesdelim
Deblois, Genevieve
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~